142 related articles for article (PubMed ID: 21063845)
1. Effect of Mad2 on paclitaxel-induced cell death in ovarian cancer cells.
Hao X; Zhou Z; Ye S; Zhou T; Lu Y; Ma D; Wang S
J Huazhong Univ Sci Technolog Med Sci; 2010 Oct; 30(5):620-5. PubMed ID: 21063845
[TBL] [Abstract][Full Text] [Related]
2. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30.
Fu Y; Ye D; Chen H; Lu W; Ye F; Xie X
Gynecol Oncol; 2007 Apr; 105(1):66-73. PubMed ID: 17234259
[TBL] [Abstract][Full Text] [Related]
3. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
4. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint.
Sudo T; Nitta M; Saya H; Ueno NT
Cancer Res; 2004 Apr; 64(7):2502-8. PubMed ID: 15059905
[TBL] [Abstract][Full Text] [Related]
5. The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ
PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338
[TBL] [Abstract][Full Text] [Related]
6. Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro.
Prencipe M; Fitzpatrick P; Gorman S; Tosetto M; Klinger R; Furlong F; Harrison M; O'Connor D; Roninson IB; O'Sullivan J; McCann A
Br J Cancer; 2009 Dec; 101(11):1900-8. PubMed ID: 19935801
[TBL] [Abstract][Full Text] [Related]
7. [Preliminary study of the prohibitin protein and paclitaxel resistance in ovarian cancer].
Tang J; Cao L; Yi H; Tang C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Dec; 37(12):1221-7. PubMed ID: 23281375
[TBL] [Abstract][Full Text] [Related]
8. Depression of MAD2 inhibits apoptosis of gastric cancer cells by upregulating Bcl-2 and interfering mitochondrion pathway.
Du Y; Yin F; Liu C; Hu S; Wang J; Xie H; Hong L; Fan D
Biochem Biophys Res Commun; 2006 Jul; 345(3):1092-8. PubMed ID: 16714000
[TBL] [Abstract][Full Text] [Related]
9. Depression of MAD2 inhibits apoptosis and increases proliferation and multidrug resistance in gastric cancer cells by regulating the activation of phosphorylated survivin.
Wang L; Yin F; Du Y; Chen B; Liang S; Zhang Y; Du W; Wu K; Ding J; Fan D
Tumour Biol; 2010 Jun; 31(3):225-32. PubMed ID: 20440596
[TBL] [Abstract][Full Text] [Related]
10. Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer.
Wang H; Fan L; Xia X; Rao Y; Ma Q; Yang J; Lu Y; Wang C; Ma D; Huang X
Int J Gynecol Cancer; 2012 Jun; 22(5):755-61. PubMed ID: 22635028
[TBL] [Abstract][Full Text] [Related]
11. Effect of spindle checkpoint on Akt2-mediated paclitaxel-resistance in A2780 ovarian cancer cells.
Zhou T; Bao Y; Ye S; Weng D; Chen G; Lu Y; Ma D; Wang S
J Huazhong Univ Sci Technolog Med Sci; 2010 Apr; 30(2):206-11. PubMed ID: 20407875
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance.
Gao S; Zhao X; Lin B; Hu Z; Yan L; Gao J
Tumour Biol; 2012 Oct; 33(5):1759-65. PubMed ID: 22684772
[TBL] [Abstract][Full Text] [Related]
13. Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling.
Zhang K; Song H; Yang P; Dai X; Li Y; Wang L; Du J; Pan K; Zhang T
Cell Prolif; 2015 Apr; 48(2):249-58. PubMed ID: 25643607
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel.
Mo QQ; Chen PB; Jin X; Chen Q; Tang L; Wang BB; Li KZ; Wu P; Fang Y; Wang SX; Zhou JF; Ma D; Chen G
Acta Pharmacol Sin; 2013 Apr; 34(4):541-8. PubMed ID: 23474708
[TBL] [Abstract][Full Text] [Related]
15. [Effect of hypoxia on the chemotherapeutic sensitivity of human ovarian cancer cells to paclitaxel and its mechanism].
Huang L; Zhang QH; Ao QL; Xing H; Lu YP; Ma D
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):96-100. PubMed ID: 17645840
[TBL] [Abstract][Full Text] [Related]
16. CDK5RAP2 is required for spindle checkpoint function.
Zhang X; Liu D; Lv S; Wang H; Zhong X; Liu B; Wang B; Liao J; Li J; Pfeifer GP; Xu X
Cell Cycle; 2009 Apr; 8(8):1206-16. PubMed ID: 19282672
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of Mad2 induces osteosarcoma cell apoptosis-involved Rad21 cleavage.
Yu L; Guo W; Zhao S; Tang J; Liu J
J Orthop Sci; 2011 Nov; 16(6):814-20. PubMed ID: 21901524
[TBL] [Abstract][Full Text] [Related]
18. Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells.
Wang X; Jin DY; Ng RW; Feng H; Wong YC; Cheung AL; Tsao SW
Cancer Res; 2002 Mar; 62(6):1662-8. PubMed ID: 11912137
[TBL] [Abstract][Full Text] [Related]
19. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism.
Poruchynsky MS; Giannakakou P; Ward Y; Bulinski JC; Telford WG; Robey RW; Fojo T
Biochem Pharmacol; 2001 Dec; 62(11):1469-80. PubMed ID: 11728383
[TBL] [Abstract][Full Text] [Related]
20. [Effects of siltuximab on the interleukin-6/Stat3 signaling pathway in ovarian cancer].
Guo YQ; Lu P; Duan ZF; Zhang Z
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):854-9. PubMed ID: 21211286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
